Sigma Of Australia To Lose Chairman, Non-Executive Director
This article was originally published in PharmAsia News
Executive SummaryAustralia's troubled Sigma Pharmaceuticals is losing its chairman and non-executive director, who announced their retirement in the face of a management shakeup
You may also be interested in...
After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.